Nanomedicines and nanodiagnostics come of age

Journal of Pharmaceutical Sciences

Volumn 102, Issue 2, 2013, Pages 305-310

  Uchegbu, Ijeoma F ^a,b   Siew, Adeline ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b NANOMERICS LTD   (United Kingdom)

Author keywords

Cancer chemotherapy; Clinical trials; Liposomes; Micelles; Nanoparticles; Polymeric drug delivery systems

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; BEVACIZUMAB; BORTEZOMIB; CANFOSFAMIDE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; MITOXANTRONE; NANOPARTICLE; PACLITAXEL; POLYMER; THALIDOMIDE; VINCRISTINE;

ARTICLE; BIOMEDICINE; BREAST CANCER; CARDIOTOXICITY; CHILL; DIAGNOSTIC TEST; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; ENCAPSULATION; FEVER; GENE THERAPY; HUMAN; KAPOSI SARCOMA; LEISHMANIASIS; LIVER CELL CARCINOMA; LUNG ASPERGILLOSIS; MELANOMA; MULTIPLE MYELOMA; NANOMEDICINE; NEPHROTOXICITY; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; RESTENOSIS; SENTINEL LYMPH NODE;

EID: 84872455315     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23377     Document Type: Article

References (34)

1. Mukherjee S, Banerjee RP. 1947. The solubilisation of quinine by bile salts. J Am Pharm Assoc 36(10):314-316.
2. Uchegbu IF. 2006. Pharmaceutical nanotechnology: Polymeric vesicles for drug and gene delivery. Expert Opin Drug Deliv 3:629-640.
3. Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, Walsh TJ. 1994. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 38(4):713-718.
4. Fu Q, Sun J, Zhang WP, Sui XF, Yan ZT, He ZG. 2009. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Patents Anticancer Drug Discov 4(3):262-272.
5. Svenson S, Wolfgang M, Hwang J, Ryan J, Eliasof S. 2011. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J Control Release 153(1):49-55.
6. Litzinger DC, Buiting AMJ, Vanrooijen N, Huang L. 1994. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1190(1):99-107.
7. Mitragotri S. 2009. In drug delivery, shape does matter. Pharm Res 26(1):232-234.
8. Blume G, Cevc G. 1990. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta 1029(1):91-97.
9. Gabizon A, Shmeeda H, Barenholz Y. 2003. Pharmacokinetics of pegylated liposomal doxorubicin-Review of animal and human studies. Clin Pharmacokinet 42(5):419-436.
10. Doshi N, Mitragotri S. 2010. Macrophages recognize size and shape of their targets. PLoS One 5(4):e10051.
11. Mahmoudi M, Hosseinkhani H, Hosseinkhani M, Boutry S, Simchi A, Journeay WS, Subramani K, Laurent S. 2011. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Chem Rev 111(2):253-280.
12. Gabizon A, Isacson R, Libson E, Kaufman B, Uziely B, Catane R, Bendor CG, Rabello E, Cass Y, Peretz T, Sulkes A, Chisin R, Barenholz Y. 1994. Clinical-studies of liposome-encapsulated doxorubicin. Acta Oncol 33(7):779-786.
13. Zhou Q, Sun X, Zeng L, Liu J, Zhang Z. 2009. A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma. Nanomedicine 5(4):419-423.
14. Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S. 2012. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 4(128):128ra139.
15. Lalatsa A, Garrett N, Moger J, Schatzlein AG, Davis C, Uchegbu IF. 2012. Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles. Mol Pharm 9(6):1764-1774.
16. Lalatsa A, Lee V, Malkinson JP, Zloh M, Schatzlein AG, Uchegbu IF. 2012. A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain. Mol Pharm 9(6):1665-1680.
17. Shukla R, Zambre A, Chanda N, Kan P, Engelbrecht H, Cutler CS, Lever JR, Smith CJ, Caldwell CW, Katti K, Upendran A, Kannan R, Katti KV. 2011. Clinical translation of radioactive gold nanoparticle-based nanoceutical (EGCG-(AuNP)-Au-198) for prostate tumor therapy. J Label Comp Radiopharm 54:S89.
18. Duncan R. 2011. Clinical status of lysosomotropic/endosomotropic polymer conjugates designed as nanomedicines. FEBS J 278:31.
19. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD. 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76(1):25-32.
20. Hiemenz JW, Walsh TJ. 1996. Lipid formulations of amphotericin B: Recent progress and future directions. Clin Infect Dis 22 Suppl 2:S133-S144.
21. Gabizon AA. 2001. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Investig 19(4):424-436.
22. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. 2000. Tumour vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 65:271-284.
23. Cortes J, Saura C. 2010. Nanoparticle albumin-bound (nab (TM))-paclitaxel: Improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. EJC SUPPLEMENTS 8(1):1-10.
24. Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA. 2012. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One 7(4):e34833.
25. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J. 1999. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer research campaign phase I/II committee. Clin Cancer Res 5(1):83-94.
26. Siew A, Le H, Thiovolet M, Gellert P, Schatzlein A, Uchegbu I. 2012. Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles. Mol Pharm 9(1):14-28.
27. Uchegbu IF, Schatzlein AG. 2006. Polymers in drug delivery. Boca Raton: Taylor and Francis.
28. New RRC. 1990. Liposomes: A practical approach. Oxford: Oxford University Press.
29. Duncan R, Hume IC, Kopeckova P, Ulbrich K, Strohalm J, Kopecek J. 1989. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukemia-L1210 in vivo. J Control Release 10(1):51-63.
30. Wang W, McConaghy AM, Tetley L, Uchegbu IF. 2001. Controls on polymer molecular weight may be used to control the size of palmitoyl glycol chitosan polymeric vesicles. Langmuir 17(3):631-636.
31. Wong PE, Tetley L, Dufes C, Chooi KW, Bolton K, Schaetzlein AG, Uchegbu IF. 2010. Polyamine aza-cyclic compounds demonstrate anti-proliferative activity in vitro but fail to control tumour growth in vivo. J Pharm Sci 99(11):4642-4657.
32. Krishna R, Mayer LD. 2000. Multidrug resistance (MDR) in cancer-Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265-283.
33. Brown MD, Schatzlein A, Uchegbu IF. 2001. Gene delivery with synthetic (non viral) carriers. Int J Pharm 229:1-21.
34. Peng Z. 2005. Current status of gendicine in China: Recombinant Ad-p53 agent for treatment of cancers. Hum Gene Ther 16:1016-1027.